BioMarin Corp (BMRN) Cash per Single Share

Corporate emblem and logo of BioMarin Pharmaceutical (BMRN)

The complexity of DNA correction in genetics carries high scientific risks; however, the cash per share forecast confirms the financial strength of BioMarin Pharmaceutical (BMRN), where the current level is around 3.79. Stability is bolstered by a powerful R&D center and strong motivation among scientists. The modernization of production facilities to reduce energy consumption and strictly control chemical emissions serves as an additional positive factor.

BioMarin Pharmaceutical Inc. (BMRN): Cash per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for BioMarin Pharmaceutical

- cash position and cash flow details:
Comprehensive company analysis:BMRN BioMarin Pharma
Manufactured product of BioMarin Pharma

This indicator determines the liquid safety cushion per ordinary share by dividing the company's total cash and cash equivalents by the number of outstanding shares. By analyzing the cash per share trend, the investor sees the current value of 3.79, which confirms the financial capacity of BioMarin Pharmaceutical (BMRN) to sustain costly genetic research and partnerships with academic clinics for rare disease therapies.